Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Adma Biologics (ADMA)

Adma Biologics (ADMA)
21.85 x 4 21.98 x 1
Post-market by (Cboe BZX)
21.86 -0.47 (-2.10%) 04/25/25 [NASDAQ]
21.85 x 4 21.98 x 1
Post-market 21.98 +0.12 (+0.55%) 19:56 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
21.61
Day High
22.35
Open 22.28
Previous Close 22.33 22.33
Volume 2,617,300 2,617,300
Avg Vol 3,606,895 3,606,895
Stochastic %K 87.83% 87.83%
Weighted Alpha +136.71 +136.71
5-Day Change +0.55 (+2.58%) +0.55 (+2.58%)
52-Week Range 6.40 - 23.64 6.40 - 23.64
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,279,446
  • Shares Outstanding, K 237,615
  • Annual Sales, $ 426,450 K
  • Annual Income, $ 197,670 K
  • EBIT $ 139 M
  • EBITDA $ 148 M
  • 60-Month Beta 0.53
  • Price/Sales 12.18
  • Price/Cash Flow 40.39
  • Price/Book 14.81

Options Overview Details

View History
  • Implied Volatility 70.14% ( +1.69%)
  • Historical Volatility 71.33%
  • IV Percentile 66%
  • IV Rank 52.84%
  • IV High 112.27% on 08/06/24
  • IV Low 22.93% on 05/16/24
  • Put/Call Vol Ratio 0.14
  • Today's Volume 1,050
  • Volume Avg (30-Day) 3,082
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 55,780
  • Open Int (30-Day) 53,626

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.16
  • Number of Estimates 1
  • High Estimate 0.16
  • Low Estimate 0.16
  • Prior Year 0.08
  • Growth Rate Est. (year over year) +100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.51 +32.40%
on 04/07/25
Period Open: 20.22
22.73 -3.83%
on 04/23/25
+1.64 (+8.11%)
since 03/25/25
3-Month
13.50 +61.93%
on 03/04/25
Period Open: 16.08
22.73 -3.83%
on 04/23/25
+5.78 (+35.95%)
since 01/24/25
52-Week
6.40 +241.56%
on 04/26/24
Period Open: 6.44
23.64 -7.53%
on 11/11/24
+15.42 (+239.44%)
since 04/25/24

Most Recent Stories

More News
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational pipeline candidate FT819 for the treatment of active...

KRYS : 168.06 (-0.63%)
JAZZ : 110.80 (+1.67%)
ADMA : 21.86 (-2.10%)
FATE : 1.2800 (-5.19%)
Ironwood Shares Tank on Regulatory Update for Apraglutide

Shares of Ironwood Pharmaceuticals IRWD plunged 31.5% yesterday after it announced regulatory updates on the next-generation GLP-2 analog, apraglutide, which is being developed for treating short bowel...

KRYS : 168.06 (-0.63%)
IRWD : 0.8885 (+1.12%)
JAZZ : 110.80 (+1.67%)
ADMA : 21.86 (-2.10%)
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to protect...

KRYS : 168.06 (-0.63%)
JAZZ : 110.80 (+1.67%)
ADMA : 21.86 (-2.10%)
ARCT : 12.91 (+0.16%)
ADMA Biologics Statement on Tariffs

ADMA : 21.86 (-2.10%)
Ensign Group Invests in Growth With New Facility Acquisitions

The Ensign Group, Inc. ENSG recently announced a series of strategic acquisitions across Washington and California. These acquisitions, effective April 1, 2025, underscore the company’s commitment to...

OPCH : 32.90 (+2.24%)
ADMA : 21.86 (-2.10%)
ENSG : 126.04 (+0.94%)
BVS : 7.65 (-1.03%)
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook

CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024.

IJR : 99.84 (-0.04%)
ADMA : 21.86 (-2.10%)
VTI : 270.64 (+0.61%)
XBI : 80.25 (-0.79%)
Adma Biologics: Q4 Earnings Snapshot

Adma Biologics: Q4 Earnings Snapshot

ADMA : 21.86 (-2.10%)
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

ADMA : 21.86 (-2.10%)
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

ADMA : 21.86 (-2.10%)
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

ADMA : 21.86 (-2.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 23.01
2nd Resistance Point 22.68
1st Resistance Point 22.27
Last Price 21.86
1st Support Level 21.53
2nd Support Level 21.20
3rd Support Level 20.79

See More

52-Week High 23.64
Last Price 21.86
Fibonacci 61.8% 17.05
Fibonacci 50% 15.02
Fibonacci 38.2% 12.99
52-Week Low 6.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective